GNMX
Corgi Genomics & Precision Medicine ETF
Price Chart
Latest Quote
$28.28
| Previous Close | $28.05 |
| Open | $28.39 |
| Day High | $28.28 |
| Day Low | $28.28 |
| Volume | 509 |
Fund Information
| Net Assets | $1.48M |
| Expense Ratio | 0.35% |
| Category | Health |
| Fund Family | Corgi Funds |
| Net Asset Value | $28.03 |
| Premium/Discount | 0.91% |
| Exchange | BTS |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $26.73 |
| RSI | 67.88 |
| ATR | 0.5386 |
| Rel Volume | 0.70 |
Performance History
| Week | +4.90% |
| Month | +11.96% |
| YTD | +10.00% |
| 10 Years | +10.00% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $28.28 | 500 |
| 2026-06-22 | $28.05 | 500 |
| 2026-06-18 | $27.98 | 100 |
| 2026-06-17 | $27.42 | 400 |
| 2026-06-16 | $26.85 | 100 |
| 2026-06-15 | $26.96 | 100 |
| 2026-06-12 | $26.43 | 100 |
| 2026-06-11 | $26.56 | 900 |
| 2026-06-10 | $26.08 | 200 |
| 2026-06-09 | $26.56 | 100 |
| 2026-06-08 | $25.92 | 100 |
| 2026-06-05 | $26.18 | 100 |
| 2026-06-04 | $27.31 | 400 |
| 2026-06-03 | $26.21 | 9,500 |
| 2026-06-02 | $25.93 | 100 |
| 2026-06-01 | $26.68 | 200 |
| 2026-05-29 | $27.00 | 200 |
| 2026-05-28 | $26.81 | 200 |
| 2026-05-27 | $25.91 | 100 |
| 2026-05-26 | $25.49 | 300 |
About Corgi Genomics & Precision Medicine ETF
The fund is an ETF that seeks to meet its objective by having Corgi Strategies, LLC actively manage the fund and, under ordinary market conditions, invest at least 80% of its net assets (plus any borrowings for investment purposes) in a portfolio of companies materially involved in the research, development, and commercialization of genomics and precision medicine technologies that enable improved disease detection, identifying and grouping patients based on genetic, molecular, or clinical characteristics to guide treatment decisions, targeted therapies, and data-driven healthcare. It is non-diversified.